Apellis Pharmaceuticals (APLS) Projected to Post Earnings on Friday

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) will likely be announcing its earnings results before the market opens on Friday, February 28th. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $197.92 million for the quarter. Investors interested in registering for the company's conference call can do so using this link.

Apellis Pharmaceuticals Stock Performance

Shares of APLS traded down $0.83 during mid-day trading on Friday, hitting $27.52. 1,335,382 shares of the company traded hands, compared to its average volume of 1,745,814. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The stock has a 50-day moving average price of $30.61 and a two-hundred day moving average price of $31.87. Apellis Pharmaceuticals has a 1 year low of $24.34 and a 1 year high of $71.90. The stock has a market cap of $3.42 billion, a price-to-earnings ratio of -13.56 and a beta of 0.96.

Insider Buying and Selling

In related news, CEO Cedric Francois sold 6,247 shares of the company's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $28.70, for a total transaction of $179,288.90. Following the completion of the transaction, the chief executive officer now owns 307,415 shares in the company, valued at approximately $8,822,810.50. This represents a 1.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel David O. Watson sold 4,965 shares of the company's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $28.70, for a total transaction of $142,495.50. Following the transaction, the general counsel now owns 107,756 shares of the company's stock, valued at approximately $3,092,597.20. This represents a 4.40 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 60,365 shares of company stock worth $1,810,479. 6.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on APLS. Robert W. Baird reduced their target price on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an "outperform" rating for the company in a report on Thursday, November 7th. Citigroup reduced their target price on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Needham & Company LLC reduced their target price on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Scotiabank reduced their target price on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a "sector perform" rating for the company in a report on Wednesday, November 6th. Finally, Morgan Stanley began coverage on shares of Apellis Pharmaceuticals in a report on Thursday, November 21st. They set an "equal weight" rating and a $31.00 target price for the company. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).